1921
Volume 77, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Because of increasing resistance to 4-aminoquinolines in Papua New Guinea, combination therapy of amodiaquine (AQ) or chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) was introduced as first-line treatment against uncomplicated malaria in 2000. The purpose of this study was to monitor efficacy of the current standard combination therapy against and malaria. Studies were conducted between 2003 and 2005 in the Simbu, East Sepik, and Madang Provinces in Papaua New Guinea according to the revised protocol of the World Health Organization (WHO) for assessment of antimalarial drug efficacy. Children between six months and seven years of age with clinically overt and parasitologically confirmed or malaria were treated according to the new policy guidelines (i.e., AQ plus SP given to patients weighing < 14 kg and CQ plus SP given to patients weighing < 14 kg). Children were monitored up to day 28 and classified according to clinical and parasitological outcome as adequate clinical and parasitological response (ACPR), early treatment failure (ETF), late clinical failure (LCF), or late parasitological failure (LPF). For malaria, polymerase chain reaction (PCR)–corrected treatment failure rates up to day 28 ranged between 10.3% and 28.8% for AQ plus SP and between 5.6% and 28.6% for CQ plus SP, depending on the region and the year of assessment. Overall treatment failure rate with AQ or CQ plus SP for malaria was 12%. Our results suggest that the current first-line treatment in Papua New Guinea is not sufficiently effective. According to the new WHO guidelines for the treatment of malaria, a rate of parasitological resistance greater than 10% in the two dominant malaria species in the country justifies a change in treatment policy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.77.947
2007-11-01
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/5/0770947.html?itemId=/content/journals/10.4269/ajtmh.2007.77.947&mimeType=html&fmt=ahah

References

  1. Grimmond TR, Donovan KO, Riley ID, 1976. Chloroquine resistant malaria in Papua New Guinea. P N G Med J 19 : 184–185.
  2. Yung AP, Bennett NM, 1976. Chloroquine-resistant falciparum malaria in Papua New Guinea. Med J Aust 2 : 320–321.
  3. Al Yaman F, Genton B, Mokela D, Narara A, Raiko A, Alpers MP, 1996. Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990–1993. P N G Med J 39 : 16–22.
  4. Darlow B, Vrbova H, 1981. Chloroquine-resistant Plasmodium falciparum malaria in Madang children. P N G Med J 24 : 96–98.
  5. Dulay IS, Gibson FD, Eyeson-Annan MB, Narara A, 1987. Chloroquine resistance in Plasmodium falciparum and its geographical distribution in Papua New Guinea. P N G Med J 30 : 281–290.
  6. Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers M, 2005. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J 48 : 141–150.
  7. Sapak P, Garner P, Baea M, Narara A, Heywood P, Alpers M, 1991. Ineffectiveness of amodiaquine against Plasmodium falciparum malaria in symptomatic young children living in an endemic malarious area of Papua New Guinea. J Trop Pediatr 37 : 185–190.
  8. Schuurkamp GJ, Kereu RK, 1989. Resistance of Plasmodium falciparum to chemotherapy with 4-aminoquinolines in the Ok Tedi area of Papua New Guinea. P N G Med J 32 : 33–44.
  9. Trenholme KR, Kum DE, Raiko AK, Gibson N, Narara A, Alpers MP, 1993. Resistance of Plasmodium falciparum to amodiaquine in Papua New Guinea. Trans R Soc Trop Med Hyg 87 : 464–466.
  10. Rieckmann KH, Davis DR, Hutton DC, 1989. Plasmodium vivax resistance to chloroquine? Lancet 2 : 1183–1184.
  11. Whitby M, Wood G, Veenendaal JR, Rieckmann K, 1989. Chloroquine-resistant Plasmodium vivax. Lancet 2 : 1395.
  12. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH, 1992. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 86 : 121–122.
  13. Spencer M, 1994. Malaria, the Australian Experience, 1843–1991. Townsville, Queensland, Australia: Australian College of Tropical Medicine.
  14. Darlow B, Vrbova H, Stace J, Heywood P, Alpers M, 1980. Fansidar-resistant falciparum malaria in Papua New Guinea. Lancet 2 : 1243.
  15. Al Yaman F, Genton B, Mokela D, Alpers MP, 1994. Resistance of Plasmodium falciparum in vivo to 3 days’ treatment with quinine and single-dose Fansidar. P N G Med J 37 : 54–56.
  16. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. Am J Trop Med Hyg 31 : 1–9.
  17. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax. Am J Trop Med Hyg 31 : 10–13.
  18. Lamont G, Darlow B, 1982. Comparison of in vitro pyrimethamine assays and in vivo response to sulphadoxine-pyrimethamine in Plasmodium falciparum from Papua New Guinea. Trans R Soc Trop Med Hyg 76 : 797–799.
  19. Kremsner PG, Krishna S, 2004. Antimalarial combinations. Lancet 364 : 285–294.
  20. White NJ, 1999. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41 : 301–308.
  21. McIntosh HM, Greenwood BM, 1998. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria–a systematic review. Ann Trop Med Parasitol 92 : 265–270.
  22. Jayatilaka KD, Taviri J, Kemiki A, Hwaihwanje I, Bulungol P, 2003. Therapeutic efficacy of chloroquine or amodiaquine in combination with sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Papua New Guinea. P N G Med J 46 : 125–134.
  23. Casey GJ, Ginny M, Uranoli M, Mueller I, Reeder JC, Genton B, Cowman AF, 2004. Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Am J Trop Med Hyg 70 : 251–255.
  24. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55 : 209–213.
  25. Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Heywood PF, Alpers MP, Stevenson A, Clancy R, 1986. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg 35 : 3–15.
  26. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, Rare L, Ginny M, Smith T, Alpers MP, 1995. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med Parasitol 89 : 377–390.
  27. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, Narara A, Gibson N, Smith T, Alpers MP, 1995. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol 89 : 359–376.
  28. Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kinibero B, Rare L, Lorry K, Kastens W, Reeder JC, Kazura JW, Zimmerman PA, 2006. Changing patterns of Plasmodium blood stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg 75 : 588–596.
  29. Mueller I, Tulloch J, Marfurt J, Hide R, Reeder JC, 2005. Malaria control in Papua New Guinea results in complex epidemiological changes. P N G Med J 48 :. 151–157.
  30. Mueller I, Kundi J, Bjorge S, Namuigi P, Saleu G, Riley ID, Reeder JC, 2006. The epidemiology of malaria in the PNG Highlands: 3) Simbu Province. P N G Med J 47 : 159–173.
  31. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization. WHO/HTM/RBM/2003.50.
  32. World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): S1–90.
  33. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, 2003. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68 : 133–139.
  34. Felger I, Beck HP, 2002. Genotyping of Plasmodium falciparum. PCR-RFLP analysis. Methods Mol Med 72 : 117–129.
  35. World Health Organization, 2001. Monitoring Antimalarial Drug Resistance. Report of a WHO Consultation. Geneva: World Health Organization. WHO/CDS/RBM/2002.39.
  36. White N, 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354 : 739–749.
  37. Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, Beck HP, Genton B, 2005. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malar J 4 : 55.
  38. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, Barnes K, Myint HY, Adjuik M, Olliaro P, Pukrittayakamee S, Looareesuwan S, Hien TT, Farrar J, Nosten F, Day NP, White NJ, 2004. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48 : 4271–4280.
  39. White NJ, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18 : 458–464.
  40. World Health Organization, 2006. Guidelines for the Treatment of Malaria. Geneva: World Health Organization. WHO/HTM/MAL/2006.1108.
  41. Wernsdorfer WH, 1994. Epidemiology of drug resistance in malaria. Acta Trop 56 : 143–156.
  42. Hwang J, Bitarakwate E, Pai M, Reingold A, Rosenthal PJ, Dorsey G, 2006. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Trop Med Int Health 11 : 789–799.
  43. McIntosh HM, Jones KL, 2005. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. Cochrane Database Syst Rev Oct 19;(4): CD000386.
  44. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun BJ, Wassilew N, Schreiber J, Anemana SD, Cramer JP, Otchwemah RN, Sauerwein RW, Eggelte TA, Bienzle U, 2005. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10 : 512–520.
  45. Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, Pettersson M, Swedberg G, Kironde F, 2005. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Trop 95 : 172–182.
  46. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsobya SL, Kilian A, Slater M, Reingold A, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, 2005. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2 : e190.
  47. Obonyo CO, Juma EA, Ogutu BR, Vulule JM, Lau J, 2007. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Trans R Soc Trop Med Hyg 101 : 117–126.
  48. Kremsner PG, Krishna S, 2002. Antimalarial cocktails–tropical flavours of the month. Lancet 360 : 1998–1999.
  49. Snounou G, Beck HP, 1998. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 14 : 462–467.
  50. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP, 1999. Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. Am J Trop Med Hyg 61 : 518–525.
  51. Craig AA, Kain KC, 1996. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis 174 : 373–379.
  52. Kirchgatter K, del Portillo HA, 1998. Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis 177 : 511–515.
  53. Taylor WR, Doan HN, Nguyen DT, Tran TU, Fryauff DJ, Gomez-Saladin E, Kain KC, Le DC, Baird JK, 2000. Assessing drug sensitivity of Plasmodium vivax to halofantrine or choroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping. Am J Trop Med Hyg 62 : 693–697.
  54. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, 2005. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 4 : 20.
  55. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL, 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56 : 621–626.
  56. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46 : 3947–3953.
  57. Young MD, Burgess RW, 1959. Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ 20 : 27–36.
  58. Baird JK, 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48 : 4075–4083.
  59. Peters W, 1998. Drug resistance in malaria parasites of animals and man. Adv Parasitol 41 : 1–62.
  60. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK, 1998. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol 92 : 265–273.
  61. Hastings MD, Maguire JD, Bangs MJ, Zimmerman PA, Reeder JC, Baird JK, Sibley CH, 2005. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother 49 : 733–740.
  62. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, 2003. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 47 : 1514–1521.
  63. Leartsakulpanich U, Imwong M, Pukrittayakamee S, White NJ, Snounou G, Sirawaraporn W, Yuthavong Y, 2002. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol 119 : 63–73.
  64. Pukrittayakamee S, Chantra A, Impson JAS, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44 : 1680–1685.
  65. Mayxay M, Pukritrayakamee S, Chotivanich K, Imwong M, Looareesuwan S, White NJ, 2001. Identification of cryptic coinfection with Plasmodium falciparum in patients presenting with vivax malaria. Am J Trop Med Hyg 65 : 588–592.
  66. Siripoon N, Snounou G, Yamogkul P, Na-Bangchang K, Thaithong S, 2002. Cryptic Plasmodium falciparum parasites in clinical P. vivax blood samples from Thailand. Trans R Soc Trop Med Hyg 96 : 70–71.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.947
Loading
/content/journals/10.4269/ajtmh.2007.77.947
Loading

Data & Media loading...

  • Received : 16 Jul 2006
  • Accepted : 23 Jun 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error